Physician profile
Haley Callahan
NPI 1154969632
$11,407.99
in general payments reported to CMS, 2019-2025
26 companies · $4,166 in 2025
The $4,166 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $78.58 · 2022: $566 · 2023: $2,137 · 2024: $4,460 · 2025: $4,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,773 · Education: $990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,772.67 |
| Education | $990.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,361.22 | 2022-2025 | |
| Janssen Biotech, INC. | $1,277.61 | 2023-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $1,154.12 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Lilly USA, LLC | $867.53 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $812.46 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $758.53 | 2023-2025 | Sotyktu |
| Genzyme Corporation | $738.81 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $701.84 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $677.08 | 2022-2025 | Dupixent, Libtayo |
| Amgen INC. | $392.13 | 2023-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $379.38 | 2023-2025 | Zoryve |
| Incyte Corporation | $379.28 | 2022-2025 | Opzelura |
| Pfizer INC. | $353.25 | 2023-2025 | |
| Dermavant Sciences, INC. | $303.93 | 2022-2024 | Vtama |
| Allergan, INC. | $273.27 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $267.99 | 2023-2025 | |
| Galderma Laboratories, L.P. | $232.72 | 2024-2025 | Nemluvio, Aklief |
| Organon LLC | $148.56 | 2024-2025 | Nexplanon |
| Celgene Corporation | $108.91 | 2024 | Sotyktu |
| Leo Pharma INC. | $59.52 | 2022-2025 | Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $44.53 | 2021-2025 | Arazlo |
| Strata Skin Sciences, INC. | $28.79 | 2025 | Xtrac |
| Vyne Pharmaceuticals INC. | $24.99 | 2021 | |
| Verrica Pharmaceuticals INC. | $21.63 | 2024 | Ycanth |
| Mylan Institutional INC. | $20.47 | 2023 | Fulphila |
| Solta Medical, A Division of Bausch Health US, LLC | $19.44 | 2025 | Clear & Brilliant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Callahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.